OPINION: Chinese Healthcare Industry Entering A ‘New Normal’?
This article was originally published in PharmAsia News
Two years after the GSK scandal broke in China, a national campaign against corruption is marching on in the country, and a series of recent events suggests that Chinese authorities are determined to clean up the healthcare industry and bring in a 'new normal'. For multinational companies, the shakeup should come as welcome news, and it is time to devise strategies to prepare for a new phase of reform in the country.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.